{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:43:07Z","timestamp":1793479387364,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007365","name":"Foundation IRCCS Polyclinic San Matteo","doi-asserted-by":"publisher","award":["P-20170026346"],"award-info":[{"award-number":["P-20170026346"]}],"id":[{"id":"10.13039\/100007365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jbspin.2024.105800","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T11:35:25Z","timestamp":1730115325000},"page":"105800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Seronegative rheumatoid arthritis: Neglected in clinical trials, a giant in clinical practice"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-7077","authenticated-orcid":false,"given":"Serena","family":"Bugatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlomaurizio","family":"Montecucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2024.105800_bib0105","doi-asserted-by":"crossref","first-page":"vii54","DOI":"10.1093\/rheumatology\/key109","article-title":"Randomized controlled trials and real-world data: differences and similarities to untangle literature data","volume":"57","author":"Monti","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105800_bib0110","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nrrheum.2017.81","article-title":"Biologics registers in RA: methodological aspects, current role and future applications","volume":"13","author":"Nikiphorou","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105800_bib0115","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nri.2016.124","article-title":"The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting","volume":"17","author":"Malmstr\u00f6m","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jbspin.2024.105800_bib0120","doi-asserted-by":"crossref","first-page":"12386","DOI":"10.3390\/ijms222212386","article-title":"The genetic, environmental, and immunopathological complexity of autoantibody-negative rheumatoid arthritis","volume":"22","author":"De Stefano","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jbspin.2024.105800_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(24)00226-1","article-title":"Prevention of seronegative rheumatoid arthritis: an entity of its own","author":"Bugatti","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105800_bib0130","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1016\/S2665-9913(23)00242-4","article-title":"Autoantibody-negative rheumatoid arthritis: still a challenge for the rheumatologist","volume":"5","author":"Bugatti","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105800_bib0135","doi-asserted-by":"crossref","first-page":"e1003296","DOI":"10.1371\/journal.pmed.1003296","article-title":"Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: a longitudinal cohort study in the Netherlands","volume":"17","author":"Matthijssen","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.jbspin.2024.105800_bib0140","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1136\/ard.2009.126748","article-title":"Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis","volume":"69","author":"Knevel","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105800_bib0145","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/ard.2009.126573","article-title":"Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA","volume":"69","author":"Nam","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105800_bib0150","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105800_bib0155","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"76","author":"Nam","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105800_bib0160","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2019-216656","article-title":"Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105800_bib0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105800_bib0170","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/annrheumdis-2022-222264","article-title":"Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic","volume":"81","author":"De Stefano","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105800_bib0175","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keae113","article-title":"The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials","author":"Takase-Minegishi","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105800_bib0180","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","article-title":"The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries","volume":"60","author":"Courvoisier","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105800_bib0185","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/annrheumdis-2022-222436","article-title":"Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis","volume":"81","author":"Bugatti","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105800_bib0190","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/rheumatology\/kead378","article-title":"Synovial and serum B cell signature of autoantibody-negative rheumatoid arthritis vs autoantibody-positive rheumatoid arthritis and psoriatic arthritis","volume":"63","author":"De Stefano","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105800_bib0195","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40070","article-title":"Secukinumab in active rheumatoid arthritis: a phase III randomized, double-blind, active comparator- and placebo-controlled study","volume":"69","author":"Blanco","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105800_bib0200","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2016-209831","article-title":"A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X24001118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X24001118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T11:02:55Z","timestamp":1737630175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X24001118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1297319X24001118"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2024.105800","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seronegative rheumatoid arthritis: Neglected in clinical trials, a giant in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2024.105800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\ufffdt\ufffd Fran\ufffdaise de Rhumatologie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105800"}}